Further trials to evaluate the effects of GLP-1 analogues on retinopathy should be performed, and new guidelines to monitor retinopathy progression in patients on GLP-1 analogues who have baseline diabetic retinopathy and poorly controlled diabetes should be initiated. The gene discussed is GCG; the disease is retinal disorder.